Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza

International Journal of Infectious Diseases

Volumn 16, Issue 5, 2012, Pages

  Metersky, Mark L ^a   Masterton, Robert G ^b   Lode, Hartmut ^c   File, Thomas M ^d   Babinchak, Timothy ^e  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

^c Department of Chest and Infectious Diseases   (Germany)

^d Northeast Ohio Medical University   (United States)

^e PFIZER INC   (United States)

Author keywords

Antibacterial agents; Antiviral agents; Influenza A virus; Influenza, human; Pneumonia, bacterial

Indexed keywords

AMIKACIN; AMPICILLIN; AZITHROMYCIN; CEFTRIAXONE; CEPHALOSPORIN; CHLORAMPHENICOL; CLINDAMYCIN; FAVIPIRAVIR; FUSIDIC ACID; GAMMA INTERFERON; GENTAMICIN; LANINAMIVIR; LINCOSAMIDE; MACROLIDE; NETILMICIN; NITRIC OXIDE; OSELTAMIVIR; PERAMIVIR; PROTEIN SYNTHESIS INHIBITOR; RIFAMPICIN; RIMANTADINE; SIALIDASE INHIBITOR; STREPTOGRAMIN; STREPTOMYCIN; TETRACYCLINE; TOBRAMYCIN; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN; ZANAMIVIR;

2009 H1N1 INFLUENZA; AGE DISTRIBUTION; BACTERIAL PNEUMONIA; BLOOD CULTURE; COMMUNITY ACQUIRED PNEUMONIA; CYTOKINE RELEASE; DEMENTIA; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SURVEILLANCE; DRUG EFFICACY; GRAM NEGATIVE BACTERIUM; HEART DISEASE; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; IMMUNOMODULATION; INFECTION RISK; INFLUENZA VIRUS A H5N1; KIDNEY DISEASE; KLEBSIELLA; LUNG DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIXED INFECTION; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PANDEMIC INFLUENZA; PATHOGENESIS; PREGNANCY; REVIEW; RHEUMATIC DISEASE; RISK ASSESSMENT; SOCIOECONOMICS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STROKE; SUPERINFECTION; SURVIVAL RATE; TREATMENT RESPONSE;

AGE FACTORS; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; HUMANS; INFLUENZA, HUMAN; PANDEMICS; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 84859649544     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2012.01.003     Document Type: Review

References (98)

1. Boyd M., Clezy K., Lindley R., Pearce R. Pandemic influenza: clinical issues. Med J Aust 2006, 185:S44-S47.
2. Echevarria-Zuno S., Mejia-Arangure J.M., Mar-Obeso A.J., Grajales-Muniz C., Robles-Perez E., Gonzalez-Leon M., et al. Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 2009, 374:2072-2079.
3. Perez-Padilla R., de la Rosa-Zamboni D., Ponce de Leon S., Hernandez M., Quinones-Falconi F., Bautista E., et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009, 361:680-689.
4. World Health Organization. World now at the start of 2009 influenza pandemic. Statement to the press by WHO Director-General Dr Margaret Chan; 11 June 2009. Available at: (accessed February 2012). http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/index.html.
5. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325:197-201.
6. Miller E., Hoschler K., Hardelid P., Stanford E., Andrews N., Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010, 375:1100-1108.
7. Bautista E., Chotpitayasunondh T., Gao Z., Harper S.A., Shaw M., Uyeki T.M., et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010, 362:1708-1719.
8. Gill J.R., Sheng Z.M., Ely S.F., Guinee D.G., Beasley M.B., Suh J., et al. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med 2010, 134:235-243.
9. Mauad T., Hajjar L.A., Callegari G.D., da Silva L.F., Schout D., Galas F.R., et al. Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med 2010, 181:72-79.
10. Shieh W.J., Blau D.M., Denison A.M., Deleon-Carnes M., Adem P., Bhatnagar J., et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol 2010, 177:166-175.
11. Morens D.M., Taubenberger J.K., Fauci A.S. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008, 198:962-970.
12. Grist N.R. Pandemic influenza 1918. Br Med J 1979, 2:1632-1633.
13. Brundage J.F., Shanks G.D. Deaths from bacterial pneumonia during 1918-19 influenza pandemic. Emerg Infect Dis 2008, 14:1193-1199.
14. Hers J.F., Masurel N., Mulder J. Bacteriology and histopathology of the respiratory tract and lungs in fatal Asian influenza. Lancet 1958, 2:1141-1143.
15. Louria D.B., Blumenfeld H.L., Ellis J.T., Kilbourne E.D., Rogers D.E. Studies on influenza in the pandemic of 1957-1958. II. Pulmonary complications of influenza. J Clin Invest 1959, 38:213-265.
16. Oseasohn R., Adelson L., Kaji M. Clinicopathologic study of thirty-three fatal cases of Asian influenza. N Engl J Med 1959, 260:509-518.
17. Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1)-United States, May-August 2009. MMWR Morb Mortal Wkly Rep 2009, 58:1071-1074. Centers for Disease Control and Prevention (CDC).
18. Louie J.K., Acosta M., Winter K., Jean C., Gavali S., Schechter R., et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009, 302:1896-1902.
19. Intensive-care patients with severe novel influenza A (H1N1) virus infection-Michigan, June 2009. MMWR Morb Mortal Wkly Rep 2009, 58:749-752. Centers for Disease Control and Prevention (CDC).
20. Webb S.A., Pettila V., Seppelt I., Bellomo R., Bailey M., Cooper D.J., et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009, 361:1925-1934.
21. Centers for Disease Control and Prevention (CDC). Questions and Answers: 2009 H1N1 and Pneumococcal Disease in the News. Available at: (accessed January 9, 2010). http://www.cdc.gov/h1n1flu/vaccination/qa_pneumococcal_disease.htm.
22. Hayden F.G., Osterhaus A.D., Treanor J.J., Fleming D.M., Aoki F.Y., Nicholson K.G., et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 1997, 337:874-880.
23. Nicholson K.G., Aoki F.Y., Osterhaus A.D., Trottier S., Carewicz O., Mercier C.H., et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000, 355:1845-1850.
24. Treanor J.J., Hayden F.G., Vrooman P.S., Barbarash R., Bettis R., Riff D., et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000, 283:1016-1024.
25. Kaiser L., Wat C., Mills T., Mahoney P., Ward P., Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003, 163:1667-1672.
26. Podewils L.J., Liedtke L.A., McDonald L.C., Hageman J.C., Strausbaugh L.J., Fischer T.K., et al. A national survey of severe influenza-associated complications among children and adults, 2003-2004. Clin Infect Dis 2005, 40:1693-1696.
27. Britten R.H. The incidence of epidemic influenza, 1918-19. Public Health Reports 1932, 47:303-339.
28. Glezen W.P. Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev 1982, 4:25-44.
29. Serfling R.E., Sherman I.L., Houseworth W.J. Excess pneumonia-influenza mortality by age and sex in three major influenza A2 epidemics, United States, 1957-58, 1960 and 1963. Am J Epidemiol 1967, 86:433-441.
30. Morens D.M., Fauci A.S. The 1918 influenza pandemic: insights for the 21st century. J Infect Dis 2007, 195:1018-1028.
31. Chowell G., Bertozzi S.M., Colchero M.A., Lopez-Gatell H., Alpuche-Aranda C., Hernandez M., et al. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med 2009, 361:674-679.
32. Mamelund S.E. A socially neutral disease? Individual social class, household wealth and mortality from Spanish influenza in two socially contrasting parishes in Kristiania 1918-19. Soc Sci Med 2006, 62:923-940.
33. Neuzil K.M., Reed G.W., Mitchel E.F., Simonsen L., Griffin M.R. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol 1998, 148:1094-1102.
34. Bisno A.L., Griffin J.P., Van Epps K.A., Niell H.B., Rytel M.W. Pneumonia and Hong Kong influenza: a prospective study of the 1968-1969 epidemic. Am J Med Sci 1971, 261:251-263.
35. Nichol K.L., Wuorenma J., von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998, 158:1769-1776.
36. Laibl V.R., Sheffield J.S. Influenza and pneumonia in pregnancy. Clin Perinatol 2005, 32:727-738.
37. Larsen J.W. Influenza and pregnancy. Clin Obstet Gynecol 1982, 25:599-603.
38. Creanga A.A., Johnson T.F., Graitcer S.B., Hartman L.K., Al-Samarrai T., Schwarz A.G., et al. Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. Obstet Gynecol 2010, 115:717-726.
39. Ellington S.R., Hartman L.K., Acosta M., Martinez-Romo M., Rubinson L., Jamieson D.J., et al. Pandemic 2009 influenza A (H1N1) in 71 critically ill pregnant women in California. Am J Obstet Gynecol 2011, 204:S21-S30.
40. Hewagama S., Walker S.P., Stuart R.L., Gordon C., Johnson P.D., Friedman N.D., et al. 2009 H1N1 influenza A and pregnancy outcomes in Victoria, Australia. Clin Infect Dis 2010, 50:686-690.
41. Jamieson D.J., Honein M.A., Rasmussen S.A., Williams J.L., Swerdlow D.L., Biggerstaff M.S., et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 2009, 374:451-458.
42. Maravi-Poma E., Martin-Loeches I., Regidor E., Laplaza C., Cambra K., Aldunate S., et al. Severe 2009 A/H1N1v influenza in pregnant women in Spain. Crit Care Med 2011, 39:945-951.
43. Finkler D. Dtsch Med Wschr 1890, 5:84-86.
44. Muir R., Wilson G.H. Observations on influenza and its complications. Br Med J 1919, 1:3-5.
45. Spooner L.H., Scott J.M., Heath E.H. A bacteriologic study of the influenza epidemic at Camp Devens, Mass. JAMA 1919, 72:155-159.
46. Wilson W.J., Steer P. Bacteriological and pathological observations on influenza as seen in France during 1918. Br Med J 1919, 1:634-635.
47. Scadding J.G. Lung changes in influenza. QJM 1937, 6:425-465.
48. Brundage J.F. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis 2006, 6:303-312.
49. Petersdorf R.G., Fusco J.J., Harter D.H., Albrink W.S. Pulmonary infections complicating Asian influenza. AMA Arch Intern Med 1959, 103:262-272.
50. Lindsay M.I., Herrmann E.C., Morrow G.W., Brown A.L. Hong Kong influenza: clinical, microbiologic, and pathologic features in 127 cases. JAMA 1970, 214:1825-1832.
51. Schwarzmann S.W., Adler J.L., Sullivan R.J., Marine W.M. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969. Arch Intern Med 1971, 127:1037-1041.
52. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., et al. Influenza-associated hospitalizations in the United States. JAMA 2004, 292:1333-1340.
53. Kallen A.J., Brunkard J., Moore Z., Budge P., Arnold K.E., Fosheim G., et al. Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. Ann Emerg Med 2009, 53:358-365.
54. Cao B., Li X.W., Mao Y., Wang J., Lu H.Z., Chen Y.S., et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med 2009, 361:2507-2517.
55. Kumar A., Zarychanski R., Pinto R., Cook D.J., Marshall J., Lacroix J., et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009, 302:1872-1879.
56. Peltola V.T., McCullers J.A. Respiratory viruses predisposing to bacterial infections: role of neuraminidase. Pediatr Infect Dis J 2004, 23:S87-S97.
57. Tashiro M., Ciborowski P., Klenk H.D., Pulverer G., Rott R. Role of Staphylococcus protease in the development of influenza pneumonia. Nature 1987, 325:536-537.
58. McCullers J.A., Rehg J.E. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis 2002, 186:341-350.
59. McNamee L.A., Harmsen A.G. Both influenza-induced neutrophil dysfunction and neutrophil-independent mechanisms contribute to increased susceptibility to a secondary Streptococcus pneumoniae infection. Infect Immun 2006, 74:6707-6721.
60. Seki M., Yanagihara K., Higashiyama Y., Fukuda Y., Kaneko Y., Ohno H., et al. Immunokinetics in severe pneumonia due to influenza virus and bacteria coinfection in mice. Eur Respir J 2004, 24:143-149.
61. Shahangian A., Chow E.K., Tian X., Kang J.R., Ghaffari A., Liu S.Y., et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest 2009, 119:1910-1920.
62. Pittet L.A., Hall-Stoodley L., Rutkowski M.R., Harmsen A.G. Influenza virus infection decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniae. Am J Respir Cell Mol Biol 2010, 42:450-460.
63. Didierlaurent A., Goulding J., Patel S., Snelgrove R., Low L., Bebien M., et al. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J Exp Med 2008, 205:323-329.
64. Hussell T., Cavanagh M.M. The innate immune rheostat: influence on lung inflammatory disease and secondary bacterial pneumonia. Biochem Soc Trans 2009, 37:811-813.
65. Ampofo K., Bender J., Sheng X., Korgenski K., Daly J., Pavia A.T., et al. Seasonal invasive pneumococcal disease in children: role of preceding respiratory viral infection. Pediatrics 2008, 122:229-237.
66. Palacios G., Hornig M., Cisterna D., Savji N., Bussetti A.V., Kapoor V., et al. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS One 2009, 4:e8540.
67. Kido H., Yokogoshi Y., Sakai K., Tashiro M., Kishino Y., Fukutomi A., et al. Isolation and characterization of a novel trypsin-like protease found in rat bronchiolar epithelial Clara cells. A possible activator of the viral fusion glycoprotein. J Biol Chem 1992, 267:13573-13579.
68. BTS Guidelines for the management of community acquired pneumonia in adults. Thorax 2001, 56(Suppl 4):IV1-IV64. British Thoracic Society.
69. Guidelines for the management of community acquired pneumonia in adults. Respirology 2006, 11:S79-S133. Committee for the Japanese Respiratory Society Guidelines for the Management of Respiratory Infections.
70. Provisional guidelines from the British Infection Society, British Thoracic Society, and Health Protection Agency in collaboration with the Department of Health. Thorax 2007, 62(Suppl 1):1-46. Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic.
71. Correa Rde A., Lundgren F.L., Pereira-Silva J.L., Frare e Silva R.L., Cardoso A.P., Lemos A.C., et al. Brazilian guidelines for community-acquired pneumonia in immunocompetent adults-2009. J Bras Pneumol 2009, 35:574-601.
72. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-S72.
73. Masterton R. The place of guidelines in hospital-acquired pneumonia. J Hosp Infect 2007, 66:116-122.
74. Masterton R., Craven D., Rello J., Struelens M., Frimodt-Moller N., Chastre J., et al. Hospital-acquired pneumonia guidelines in Europe: a review of their status and future development. J Antimicrob Chemother 2007, 60:206-213.
75. Barlow G.D. Swine flu and antibiotics. J Antimicrob Chemother 2009, 64:889-894.
76. Infectious Diseases Society of America (IDSA). Influenza H1N1: frontline questions and expert opinion answers. Available at: (accessed April 18, 2011). http://www.idsociety.org/FluFAQ.
77. Shun-Shin M., Thompson M., Heneghan C., Perera R., Harnden A., Mant D. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials. BMJ 2009, 339:b3172.
78. Zarychanski R., Stuart T.L., Kumar A., Doucette S., Elliott L., Kettner J., et al. Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. CMAJ 2010, 182:257-264.
79. McCullers J.A. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J Infect Dis 2004, 190:519-526.
80. McGeer A., Green K.A., Plevneshi A., Shigayeva A., Siddiqi N., Raboud J., et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007, 45:1568-1575.
81. McCullers J.A., English B.K. Improving therapeutic strategies for secondary bacterial pneumonia following influenza. Future Microbiol 2008, 3:397-404.
82. Duval X., van der Werf S., Blanchon T., Mosnier A., Bouscambert-Duchamp M., Tibi A., et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med 2010, 7:e1000362.
83. Nau R., Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 2002, 15:95-110.
84. Buckingham S.C., McCullers J.A., Lujan-Zilbermann J., Knapp K.M., Orman K.L., English B.K. Early vancomycin therapy and adverse outcomes in children with pneumococcal meningitis. Pediatrics 2006, 117:1688-1694.
85. Karlstrom A., Boyd K.L., English B.K., McCullers J.A. Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. J Infect Dis 2009, 199:311-319.
86. Sato K., Suga M., Akaike T., Fujii S., Muranaka H., Doi T., et al. Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice. Am J Respir Crit Care Med 1998, 157:853-857.
87. Yamaya M., Shinya K., Hatachi Y., Kubo H., Asada M., Yasuda H., et al. Clarithromycin inhibits type A seasonal influenza virus infection in human airway epithelial cells. J Pharmacol Exp Ther 2010, 333:81-90.
88. Kim S.H., Hong S.B., Yun S.C., Choi W.I., Ahn J.J., Lee Y.J., et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med 2011, 183:1207-1214.
89. Viasus D., Pano-Pardo J.R., Cordero E., Campins A., Lopez-Medrano F., Villoslada A., et al. Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J Infect 2011, 62:193-199.
90. Aspa J., Rajas O., Rodriguez de Castro F., Huertas M.C., Borderias L., Cabello F.J., et al. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 2006, 27:1010-1019.
91. Dwyer R., Ortqvist A., Aufwerber E., Henriques Normark B., Marrie T.J., Mufson M.A., et al. Addition of a macrolide to a ss-lactam in bacteremic pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 2006, 25:518-521.
92. Martinez J.A., Horcajada J.P., Almela M., Marco F., Soriano A., Garcia E., et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003, 36:389-395.
93. Mufson M.A., Stanek R.J. Revisiting combination antibiotic therapy for community-acquired invasive Streptococcus pneumoniae pneumonia. Clin Infect Dis 2006, 42:304-306.
94. Weiss K., Low D.E., Cortes L., Beaupre A., Gauthier R., Gregoire P., et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 2004, 11:589-593.
95. Waterer G.W., Rello J. Choosing the right combination therapy in severe community-acquired pneumonia. Crit Care 2006, 10:115.
96. Weiss K., Tillotson G.S. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia. Chest 2005, 128:940-946.
97. Blackburn R.M., Henderson K.L., Lillie M., Sheridan E., George R.C., Deas A.H., et al. Empirical treatment of influenza-associated pneumonia in primary care: a descriptive study of the antimicrobial susceptibility of lower respiratory tract bacteria (England, Wales and Northern Ireland, January 2007-March 2010). Thorax 2011, 66:389-395.
98. Mortensen E.M., Restrepo M.I., Anzueto A., Pugh J. The impact of empiric antimicrobial therapy with a beta-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Crit Care 2005, 10:R8.